Confirmatory HIV testing can substantially reduce the number of infants in South Africa who may be falsely diagnosed as HIV-infected and started on unneeded treatment, according to a new study published this week in PLOS Medicine by Lorna Dunning of the University of Cape Town, South Africa, and colleagues. Confirmatory testing is recommended by the World Health Organization and South African guidelines, but in many settings, uptake is low.
The specificity of nucleic acid amplification tests (NAATs) for early infant HIV diagnosis (EID) is less than 100 percent, meaning some infants are incorrectly diagnosed with HIV. Using an existing computer simulation model of pediatric HIV, the authors of the new study examined the impact of a second NAAT in infants to confirm a first positive result. They assumed a NAAT cost of $25, specificity of 99.6%, and sensitivity of 100%.
Without confirmatory testing, 128 of every 1000 infants initiating antiretroviral therapy (ART) were actually HIV-uninfected, due to false-positive diagnoses; with confirmatory testing, only 1 out of 1000 infants initiating ART was truly uninfected. Because a second round of testing averted costly and unnecessary HIV care and ART in HIV-uninfected infants, the additional testing was projected to be cost-saving over a lifetime, costing $1,790 per infant tested, compared to $1,830 without confirmatory testing. The study went on to show that when confirmatory testing is used, ART should be initiated immediately after a first positive NAAT. Waiting even one month until the return of a second test to initiate ART can markedly reduce both short-term and long-term survival for HIV-infected infants.
"We find that use of a second NAAT for confirmatory testing in EID programmes will substantially reduce the proportion of infants incorrectly diagnosed as HIV-infected and initiated on ART in settings with low infant HIV transmission rates like South Africa" says Ms. Dunning. "While projected cost differences are small, confirmatory testing is likely to be cost-saving under a wide range of scenarios in South Africa," notes Dr. Andrea Ciaranello of Massachusetts General Hospital and Harvard Medical School, senior author on the study. "Concerns about the cost of the second test itself should not be the reason to avoid this important intervention."
This work was supported by the World Health Organization (to AC); the National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD; award R01 HD079214 to AC) and the National Institute of Allergy and Infectious Diseases (NIAID; awards R01 AI058736 [to KAF], and R37 AI093269 [to RPW]). No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
The authors have declared that no competing interests exist.
Dunning L, Francke JA, Mallampati D, MacLean RL, Penazzato M, Hou T, et al. (2017) The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: A cost-effectiveness analysis. PLoS Med 14(11): e1002446. https:/
Division of Epidemiology and Biostatistics, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa
Medical Practice Evaluation Centre, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois, United States of America
Department of HIV/AIDS, World Health Organization, Geneva, Switzerland
Centre for Infectious Diseases Epidemiology & Research, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa
ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, New York, United States of America
College of Physicians & Surgeons, Columbia University, New York, New York, United States of America
Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America
Center for AIDS Research, Harvard University, Boston, Massachusetts, United States of America
Inserm, U1027, University of Toulouse 3, Toulouse, France
Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America
IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER: